Dr. James Costin has an extensive career in drug development in the pharmaceutical industry and is an interventional cardiologist by training. He completed his MD at Emory University School of Medicine and his house officer training at Yale University School of Medicine consisting of internship, residency, cardiology fellowship. Thereafter, he joined the cardiology section’s academic staff at Yale where he was primarily involved with the cardiac catherization laboratory and research. Following his position at Yale, he joined ICI’s pharmaceutical division where he was involved with all phases of drug development with a focus on marketing and Phase 4 studies. Dr. Costin joined Carter-Wallace pharmaceutical company as Vice President of Medical Affairs, and quickly advanced to Vice President of Research and Development, and ultimately Corporate Vice President of Medical and Scientific Affairs and Chief Medical Officer. While at Carter Wallace, Dr Costin established a drug development partnership with Geistlich Pharma AG. Following Carter-Wallace’s sale, he was Vice President and Chief Medical Officer of a new company, Perosphere, Inc., where he directed the development of a drug in the anticoagulation field. For the past 6 years, Dr Costin has consulted again with Geistlich Pharma to head the research and development of GP-2250 program.